Sugarloaf Wealth Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-600
Closed -$33K 861
2022
Q2
$33K Hold
600
0.01% 348
2022
Q1
$33K Hold
600
0.01% 335
2021
Q4
$34K Hold
600
0.01% 353
2021
Q3
$29K Hold
600
0.01% 356
2021
Q2
$25K Hold
600
0.01% 382
2021
Q1
$20 Hold
600
0.01% 405
2020
Q4
$21K Hold
600
0.01% 372
2020
Q3
$21K Hold
600
0.01% 347
2020
Q2
$20K Hold
600
0.01% 350
2020
Q1
$18K Hold
600
0.01% 350
2019
Q4
$17K Buy
+600
New +$16.6K 0.01% 393

Other funds holding NVO

Sugarloaf Wealth Management's NVO Position: Q3 2022 in Review

Sugarloaf Wealth Management sold out of Novo Nordisk (NVO) in Q3 2022, closing a stake of 600 shares — an estimated $33K sold.

Sugarloaf Wealth Management first reported a position in NVO in Q4 2019 and held it in 11 quarters. The position peaked at $34K in Q4 2021. 907 funds tracked by Wall St. Rank hold NVO as of Q3 2022.

  • Sugarloaf Wealth Management reported no remaining Novo Nordisk position as of Q3 2022 after selling out during the quarter.
  • Sugarloaf Wealth Management sold 600 Novo Nordisk shares in Q3 2022, an estimated $33K.
  • Sugarloaf Wealth Management first reported a position in Novo Nordisk in Q4 2019 and held it in 11 quarters.
  • Sugarloaf Wealth Management's Novo Nordisk position peaked at $34K in Q4 2021.
  • 907 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2022.

Based on Sugarloaf Wealth Management's 13F filing for Q3 2022, filed 11 Oct 2022.